Home|DSIJArticleDetail

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP
Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP

Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg.

DSIJ Intelligence-1 Article rating: 5.0

The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas where its 1500 scientists dedicate their efforts.

DSIJ MINDSHARE

Mkt Commentary16-Apr, 2025

Mindshare16-Apr, 2025

Mindshare16-Apr, 2025

Multibaggers16-Apr, 2025

Quarterly Results16-Apr, 2025

Knowledge

General22-Mar, 2025

MF14-Mar, 2025

MF14-Mar, 2025

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual
BSE Enlistment No. 5307

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual
BSE Enlistment No. 1346

Registered and Correspondence Office Address :
DSIJ PVT LTD. Office No - 409,
Solitaire Business Hub, Kalyani Nagar, Pune - 411006
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Conditions | Privacy Statement | WhiteList